Condition: Lupus Erythematosus, Systemic · Lupus Nephritis · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| University Of Alabama | Birmingham, Alabama, United States | Recruiting |
| Loma Linda University | San Bernardino, California, United States | Recruiting |
| UCSF | San Francisco, California, United States | Recruiting |
| UCSF | San Francisco, California, United States | Recruiting |
| Sutter Health Network | San Pablo, California, United States | Recruiting |
| Ann and Robert H Lurie Childs Hosp | Chicago, Illinois, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| University Of Iowa | Iowa City, Iowa, United States | Recruiting |
| University of Kentucky | Lexington, Kentucky, United States | Recruiting |
| Tufts Medical Center | Boston, Massachusetts, United States | Recruiting |
| Boston Medical Center | Boston, Massachusetts, United States | Recruiting |
| WA Uni School Of Med | St Louis, Missouri, United States | Recruiting |
+ 89 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06581198